AptarGroup, Inc. (NYSE: ATR) FY2025 revenue ~$3.55-3.75B (+3-7%) with adj. EPS ~$5.65-6.20 reflecting continued post-2024 ~$3.55-3.75B aggregate Pharma + Beauty + Closures dispensing solutions revenue (~$1.70-1.80B aggregate Pharma + ~$1.25-1.35B aggregate Beauty + ~$0.55-0.60B aggregate Closures) under continued President + CEO Stephan Tanda since 2018 (~7-year tenure as AptarGroup CEO; selected post-2018 succeeded Steve Hagge retirement). One of the largest US specialty Pharma + Beauty + Closures dispensing solutions companies. Founded 1940 as Calmar in Crystal Lake Illinois (~85-year heritage; selected pioneer Pharma + Beauty + Closures dispensing solutions specialty; selected post-1992 AptarGroup reorganization); selected post-April 1993 NYSE IPO via Pittway demerger; selected post-1993-2025 ~$3B+ cumulative tuck-in M&A platform expansion (Emsar Brescia 2002 + CSP Technologies Active Material Science 2018 $555M+ + Nanopharm 2019); selected post-2018 Stephan Tanda CEO appointment; selected post-2024 Pediatric Naloxone Nasal Spray + GLP-1 Auto-Injector + Pre-filled syringe boom. Headquartered in Crystal Lake Illinois; ~12,000-13,000 employees globally. Three primary segments: Pharma ~48%+ ($1.70-1.80B), Beauty + Home ~35%+ ($1.25-1.35B), Closures ~16%+ ($0.55-0.60B). Geographic mix: North America ~35%+ + Europe ~40% + Asia Pacific ~20% + selected various aggregate ~5%. Pharma Drug Delivery + Active Material Science pipeline (~$1.70-1.80B): ~$1.70-1.80B Pharma revenue (~48%+); selected primary Prescription Drug Delivery + Inhalation (MDI + DPI) + Nasal Spray (Nasonex + Flonase + post-2024 Narcan Pediatric Naloxone) + Injectables (Auto-Injectors + Pre-filled syringes); selected ~$130-150B global Pharma Dispensing TAM; selected ~$100-150 Pharma value per device; selected post-2024 GLP-1 Auto-Injector + Pre-filled syringe boom + Pediatric Naloxone Nasal Spray growth. Beauty + Home + Personal Care + Closures pipeline: selected continued post-2024 Beauty + Home ~$1.25-1.35B revenue (~35%+; Fragrance + Skincare + Color Cosmetics + Personal Care + Home Care + Estée Lauder + L'Oréal + Procter & Gamble + Unilever + Coty + Avon customers); selected Closures ~$0.55-0.60B revenue (~16%+; Food + Beverage + Sports Drink). President + CEO Stephan Tanda since 2018 (~7-year tenure); CFO Vanessa Kanu. Capital position: ~$1.80 aggregate annual dividend (~30%+ aggregate payout ratio; ~1.0-1.4% aggregate dividend yield; ~32+ year dividend increase track record); ~$50-150M aggregate FY2025 buybacks; aggregate capital return ~$170-275M FY2025; net leverage ~1.0-1.5x Net Debt/EBITDA; investment-grade A3/A- credit rating; ~66-68M diluted shares; weighted average debt maturity ~6-7 years. FY2026 thesis: Pharma Drug Delivery + Active Material Science pipeline + Beauty + Home + Personal Care + Closures pipeline + post-2024 GLP-1 Auto-Injector + Pre-filled syringe boom + Pediatric Naloxone Nasal Spray + ~32+ year dividend increase track record + ~$130-150B global Pharma Dispensing TAM. Risks: Bemis + Berry Global (post-2024 Amcor merger pending) + Amcor + Sealed Air + Silgan Holdings + Crown Holdings + Becton Dickinson + West Pharmaceutical Services + Albea competitive displacement + post-2024 GLP-1 Auto-Injector + Pre-filled syringe demand cycle considerations + Inhalation + Nasal Spray prescription cycle considerations + Estée Lauder + L'Oréal + Procter & Gamble + Unilever + Coty + Avon customer concentration considerations + Federal Reserve interest rate cycle considerations + post-2018 Stephan Tanda CEO succession planning considerations.

[ATR] AptarGroup Thesis 2026: Pharma Drug Delivery Drives Dispensing Closures Capital Return

Key Takeaways

ATR FY2025 revenue ~$3.55-3.75B (+3-7% YoY) with adj. EPS ~$5.65-6.20 reflecting continued post-2024 ~~$3.55-3.75B aggregate Pharma + Beauty + Closures dispensing solutions revenue (~~$1.70-1.80B aggregate Pharma + ~$1.25-1.35B aggregate Beauty + ~$0.55-0.60B aggregate Closures) under continued President + CEO Stephan Tanda since 2018 (~7-year tenure as AptarGroup CEO; selected post-2018 succeeded Steve Hagge retirement).
Pharma Drug Delivery + Active Material Science Pipeline (~$1.70-1.80B revenue): ~$1.70-1.80B aggregate Pharma revenue (~48%+ revenue mix); selected primary Prescription Drug Delivery + selected various aggregate Inhalation (Metered-Dose Inhaler MDI + Dry Powder Inhaler DPI) + Nasal Spray (Nasonex + Flonase + selected various aggregate post-2024 Narcan Pediatric Naloxone) + selected various aggregate Injectables (Auto-Injectors + Pre-filled syringes) + selected various aggregate ~$130-150B aggregate global Pharma Dispensing TAM + selected various aggregate ~$100-150 aggregate Pharma value per device + selected various aggregate post-2024 GLP-1 Auto-Injector + Pre-filled syringe boom + selected various aggregate Pediatric Naloxone Nasal Spray growth.
Beauty + Home + Personal Care + Closures Pipeline: selected continued post-2024 selected various aggregate Beauty + Home aggregate ~$1.25-1.35B aggregate revenue (~35%+ aggregate revenue mix; selected primary Beauty (Fragrance + Skincare + Color Cosmetics + Personal Care) + Home Care + selected various aggregate Estée Lauder + L'Oréal + Procter & Gamble + Unilever + Coty + Avon + selected various aggregate Beauty + Home customer aggregate) + selected various aggregate Closures aggregate ~$0.55-0.60B aggregate revenue (~16%+ aggregate revenue mix; selected primary Food + Beverage + selected various aggregate Sports Drink + selected various aggregate Closure dispensing solutions).
Capital position + balance sheet: ~$1.80 aggregate annual dividend (~30%+ aggregate payout ratio; ~1.0-1.4% aggregate dividend yield; selected ~32+ year aggregate dividend increase track record); ~$50-150M aggregate FY2025 buybacks; aggregate capital return ~$170-275M FY2025; net leverage ~1.0-1.5x Net Debt/EBITDA; investment-grade A3/A- credit rating; ~66-68M diluted shares; weighted average debt maturity ~6-7 years.
FY2026 thesis catalysts: Pharma Drug Delivery + Active Material Science pipeline (~~$1.70-1.80B + Inhalation + Nasal Spray + Injectables + post-2024 GLP-1 Auto-Injector boom + Pediatric Naloxone Nasal Spray) + Beauty + Home + Personal Care + Closures pipeline (~~$1.80-1.95B aggregate combined) + selected ~32+ year aggregate dividend increase track record + selected ~$130-150B aggregate global Pharma Dispensing TAM.

Company Background

AptarGroup, Inc. (NYSE: ATR) is one of the largest US specialty Pharma + Beauty + Closures dispensing solutions companies, founded 1940 as Calmar by selected various aggregate co-founders in Crystal Lake Illinois (~85-year heritage; selected pioneer Pharma + Beauty + Closures dispensing solutions specialty; selected post-1992 AptarGroup reorganization). Selected post-April 1993 NYSE IPO via Pittway demerger; selected post-1993-2025 selected various aggregate ~$3B+ aggregate cumulative tuck-in M&A platform expansion (selected post-2002 Emsar Brescia acquisition + selected post-2018 CSP Technologies Active Material Science acquisition ($555M+) + selected post-2019 Nanopharm acquisition + selected various aggregate Pharma + Beauty + Closures acquisitions); selected post-2018 Stephan Tanda CEO appointment (succeeded Steve Hagge retirement); selected post-2024 selected various aggregate Pediatric Naloxone Nasal Spray + GLP-1 Auto-Injector + Pre-filled syringe boom; HQ Crystal Lake Illinois; ~12,000-13,000 employees globally; selected ~$130-150B aggregate global Pharma Dispensing TAM.

ATR operates 3 primary segments: Pharma ~~48%+ revenue (~~$1.70-1.80B), Beauty + Home ~~35%+ revenue (~~$1.25-1.35B), Closures ~~16%+ revenue (~~$0.55-0.60B). Geographic mix: North America ~35%+ + Europe ~40% + Asia Pacific ~20% + selected various aggregate ~5%.

Capital position: ~$1.80 aggregate annual dividend (~30%+ aggregate payout ratio; ~1.0-1.4% aggregate dividend yield; selected ~32+ year aggregate dividend increase track record); ~$50-150M aggregate FY2025 buybacks; aggregate capital return ~$170-275M FY2025; net leverage ~1.0-1.5x Net Debt/EBITDA; investment-grade A3/A- credit rating; ~66-68M diluted shares; weighted average debt maturity ~6-7 years.

Pharma Drug Delivery + Active Material Science Pipeline (~$1.70-1.80B Revenue)

The Pharma Drug Delivery + Active Material Science pipeline is ATR's foundation thesis: ~$1.70-1.80B aggregate Pharma revenue (~48%+ revenue mix) + selected primary Prescription Drug Delivery + selected various aggregate Inhalation (Metered-Dose Inhaler MDI + Dry Powder Inhaler DPI) + Nasal Spray (Nasonex + Flonase + selected various aggregate post-2024 Narcan Pediatric Naloxone) + selected various aggregate Injectables (Auto-Injectors + Pre-filled syringes) + selected various aggregate ~$130-150B aggregate global Pharma Dispensing TAM + selected various aggregate ~$100-150 aggregate Pharma value per device + selected various aggregate post-2024 GLP-1 Auto-Injector + Pre-filled syringe boom + selected various aggregate Pediatric Naloxone Nasal Spray growth. Selected primary ATR platform: post-2018 CSP Technologies Active Material Science integration + post-2024 GLP-1 Auto-Injector boom.

FY2025 Pharma dynamics ($1.70-1.80B aggregate Pharma revenue): selected continued post-2024 ~+5-10% aggregate Pharma revenue growth (cyclical post-2024 GLP-1 Auto-Injector + Pre-filled syringe boom + selected various aggregate Pediatric Naloxone Nasal Spray growth + selected various aggregate Inhalation + Nasal Spray + Injectables continued demand) + ~$1.70-1.80B aggregate Pharma revenue + selected various aggregate ~$100-150 aggregate Pharma value per device + selected various aggregate ~$130-150B aggregate global Pharma Dispensing TAM. Selected post-2024 ~$1.50-2.50 incremental annual EPS contribution as Pharma Drug Delivery + Active Material Science pipeline drives incremental margin.

FY2026 catalyst: continued Pharma Drug Delivery + Active Material Science pipeline + ~$1.50-2.50 incremental annual EPS contribution under continued Stephan Tanda leadership (~7-year tenure). Selected aggregate ~$1.80-1.95B aggregate Pharma revenue + selected various ~+5-8% aggregate Pharma growth + selected various aggregate ~$100-150 aggregate Pharma value per device + selected various aggregate post-2024 GLP-1 Auto-Injector + Pre-filled syringe boom continuation + selected various aggregate Pediatric Naloxone Nasal Spray expansion. Risks: Bemis (private) + Berry Global (BERY; post-2024 Amcor merger pending) + Amcor (AMCR) + Sealed Air (SEE) + Silgan Holdings (SLGN) + Crown Holdings (CCK) + Becton Dickinson (BDX; Pre-filled syringes) + West Pharmaceutical Services (WST; Pre-filled syringes) + selected various aggregate global Pharma + Beauty + Closures dispensing competitive displacement + post-2024 GLP-1 Auto-Injector + Pre-filled syringe demand cycle considerations + Inhalation + Nasal Spray prescription cycle considerations + Federal Reserve interest rate cycle considerations.

Beauty + Home + Personal Care + Closures Pipeline

The Beauty + Home + Personal Care + Closures pipeline is ATR's primary growth thesis: selected continued post-2024 selected various aggregate Beauty + Home aggregate ~$1.25-1.35B aggregate revenue (~35%+ aggregate revenue mix; selected primary Beauty (Fragrance + Skincare + Color Cosmetics + Personal Care) + Home Care + selected various aggregate Estée Lauder + L'Oréal + Procter & Gamble + Unilever + Coty + Avon + selected various aggregate Beauty + Home customer aggregate) + selected various aggregate Closures aggregate ~$0.55-0.60B aggregate revenue (~16%+ aggregate revenue mix; selected primary Food + Beverage + selected various aggregate Sports Drink + selected various aggregate Closure dispensing solutions).

FY2025 Beauty + Home + Closures dynamics: selected primary post-2024 ~$1.25-1.35B aggregate Beauty + Home revenue + selected various aggregate Fragrance + Skincare + Color Cosmetics + Personal Care + Home Care + selected various aggregate Estée Lauder + L'Oréal + Procter & Gamble + Unilever + Coty + Avon Beauty + Home customers + selected various aggregate ~$0.55-0.60B aggregate Closures revenue (Food + Beverage + Sports Drink). Selected post-2024 ~$0.85-1.20 incremental annual EPS contribution as Beauty + Home + Personal Care + Closures pipeline drives incremental margin.

FY2026 catalyst: continued Beauty + Home + Personal Care + Closures pipeline + ~$0.85-1.20 incremental EPS contribution. Selected aggregate ~$1.30-1.40B aggregate Beauty + Home revenue + selected various aggregate ~$0.55-0.65B aggregate Closures revenue + selected various aggregate Fragrance + Skincare + Color Cosmetics + Personal Care + Home Care continued growth + selected various aggregate Estée Lauder + L'Oréal + Procter & Gamble + Unilever + Coty + Avon customer + selected various aggregate Sustainability + Recyclable Closures innovation. Risks: Bemis + Berry Global + Amcor + Sealed Air + Silgan Holdings + Crown Holdings + Aptar competitor + Albea + Aprijet + selected various aggregate global Beauty + Home + Closures competitive displacement + Estée Lauder + L'Oréal + Procter & Gamble + Unilever + Coty + Avon customer concentration considerations + Federal Reserve interest rate cycle considerations.

Capital Position + Balance Sheet

Capital position + balance sheet: ~$1.80 aggregate annual dividend (~30%+ aggregate payout ratio; ~1.0-1.4% aggregate dividend yield; selected ~32+ year aggregate dividend increase track record) + ~$50-150M aggregate FY2025 buybacks + aggregate capital return ~$170-275M FY2025 + net leverage ~1.0-1.5x Net Debt/EBITDA + investment-grade A3/A- credit rating + ~66-68M diluted shares + weighted average debt maturity ~6-7 years.

FY2026 catalyst: continued ~$170-310M aggregate annual capital return + selected continued ~1.0-1.4% aggregate dividend yield + selected continued ~$1.80-1.95 aggregate annual dividend (post-FY2025 ~33+ year continued dividend increase track record) + selected continued ~1.0-1.5x net leverage + selected various aggregate ~$32+ year aggregate dividend increase track record continuation. Selected ~30%+ aggregate payout ratio + selected investment-grade A3/A- credit rating support continued capital return + Pharma + Beauty + Closures + tuck-in M&A capacity.

Key Core Metrics

FY2025 revenue ~$3.55-3.75B (+3-7% YoY) vs $3.50B FY2024; adj. EPS ~$5.65-6.20
3 segments: Pharma ~48%+ ($1.70-1.80B) + Beauty + Home ~35%+ ($1.25-1.35B) + Closures ~16%+ ($0.55-0.60B)
Geographic mix: North America ~35%+ + Europe ~40% + Asia Pacific ~20% + selected various aggregate ~5%
Pharma: Prescription Drug Delivery + Inhalation (MDI + DPI) + Nasal Spray (Nasonex + Flonase + Narcan Pediatric Naloxone) + Injectables (Auto-Injectors + Pre-filled syringes)
Pharma value per device: ~$100-150
Global Pharma Dispensing TAM: ~$130-150B
post-2024 GLP-1 Auto-Injector + Pre-filled syringe boom: Eli Lilly Mounjaro + Zepbound + Novo Nordisk Ozempic + Wegovy
Beauty + Home customers: Estée Lauder + L'Oréal + Procter & Gamble + Unilever + Coty + Avon
Closures: Food + Beverage + Sports Drink + selected various aggregate
~32+ year aggregate dividend increase track record
Net leverage ~1.0-1.5x Net Debt/EBITDA
~66-68M diluted shares; ~$170-275M total capital return FY2025
Dividend ~$1.80 annual (~30%+ payout; ~1.0-1.4% yield; ~32+ year increase track)
~$50-150M aggregate FY2025 buybacks
Investment-grade A3/A- credit rating

Market Evaluation

ATR FY2026 market evaluation: at ~$130-180 share price + ~66-68M diluted shares = ~$9-12B market cap; ~$1.80 aggregate annual dividend + ~1.0-1.4% aggregate dividend yield. Selected primary ATR peers: Bemis (private) + Berry Global (BERY; post-2024 Amcor merger pending) + Amcor (AMCR, ~$15-18B Mcap; Packaging) + Sealed Air (SEE, ~$5-6B; Packaging) + Silgan Holdings (SLGN, ~$5-7B; Closures) + Crown Holdings (CCK, ~$10-12B; Metal Containers) + Becton Dickinson (BDX, ~$60-70B; Pre-filled syringes) + West Pharmaceutical Services (WST, ~$25-30B; Pre-filled syringes) + Albea (private) + selected various aggregate global Pharma + Beauty + Closures dispensing companies. Selected ATR ~22-30x P/E (premium Pharma + Beauty growth) + selected ~15-18x EV/EBITDA + selected ~1.0-1.4% dividend yield + selected aggregate ~$3.75-3.95B aggregate FY2026 revenue + selected aggregate ~$6.00-6.65 aggregate FY2026 EPS + selected aggregate ~$170-310M aggregate FY2026 capital return + selected aggregate Pharma + Beauty + Closures pipeline. FY2026 base case: ~$3.75-3.95B aggregate revenue + ~$6.00-6.65 adj. EPS + ~$170-310M aggregate capital return. Bull case: Pharma post-2024 GLP-1 Auto-Injector + Pre-filled syringe boom acceleration + Pediatric Naloxone Nasal Spray expansion + Beauty + Home + Closures cycle recovery + post-2018 CSP Technologies Active Material Science integration synergies + post-2024 Sustainability + Recyclable Closures innovation drives ~$3.85-4.10B aggregate revenue + ~$6.50-7.20 EPS. Bear case: Bemis + Berry Global + Amcor + Sealed Air + Silgan Holdings + Crown Holdings + Becton Dickinson + West Pharmaceutical Services + Albea competitive intensification + post-2024 GLP-1 Auto-Injector + Pre-filled syringe demand cycle considerations + Inhalation + Nasal Spray prescription cycle considerations + Estée Lauder + L'Oréal + Procter & Gamble + Unilever + Coty + Avon customer concentration considerations + Federal Reserve interest rate cycle considerations + post-2018 Stephan Tanda CEO succession planning considerations drives ~$3.55-3.75B revenue + ~$5.25-5.85 EPS. The thesis depends on Pharma Drug Delivery + Active Material Science + Beauty + Home + Closures + ~32+ year dividend track record.